Neurona Therapeutics is advancing its cell therapy, NRTX-1001, into a Phase 3 clinical trial for drug-resistant epilepsy—a major milestone for patients with mesial temporal lobe epilepsy (MTLE), the most common form of epilepsy in adults. This potential one-time treatment aims to provide an alternative to existing surgical interventions. With positive early clinical data and an RMAT designation from the FDA, NRTX-1001 has the potential to offer patients with MTLE new treatment options. CIRM supported the Phase 1/2 unilateral MTLE clinical trial with an $8 million grant and has supported Neurona's research from the initial discovery research stage to the ongoing first-in-human clinical trial.
